Skip to main content
SpringerLink
Log in

HIV Biosafety: Guidelines and Regulations

  • Chapter
AIDS Testing

Abstract

Risk has been defined as hazard plus outrage. When the outrage (perceived concern, outcry, demand for change) concerning an event is high, even when the hazard is low, activities associated with the event are believed to be risky. Alternatively, even when the hazard has been quantified to be real, the risk is construed to be low if the event is perceived to be acceptable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hance BJ, Caron C. Sandman PM. Industry Risk Communication Manual. Boca Raton, FL: CRC Press/Lewis Publishers,1990

    Google Scholar 

  2. Grady GF, et al. Hepatitis B immune globulin for accidental exposures among medical personnel. J Infect Dis 1978;138:625–638

    Article  PubMed  CAS  Google Scholar 

  3. Seef LB, et al. Type B hepatitis after needlestick exposure: prevention with hepatitis B immune globulin. Ann Intern Med 1978;88:285–293

    Google Scholar 

  4. CDC. Unpublished data, 1993

    Google Scholar 

  5. Bell DM. Human immunodeficiency virus transmission in health care settings: risk and risk reduction. Am J Med 1991;91(suppl 3B):294S–300S

    Article  PubMed  CAS  Google Scholar 

  6. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers; Italian Multicenter Study, the Italian study group on occupational risk of HIV infection. Arch Intern Med 1993;153:1451–1458

    Article  PubMed  CAS  Google Scholar 

  7. Centers for Disease Control. HIV/AIDS Surveillance Report. 1993;5(2):13

    Google Scholar 

  8. Sulkin SE, Pike RM. Viral infections contracted in the laboratory. N Engl J Med 1949;241:205–213

    Article  PubMed  CAS  Google Scholar 

  9. Pike RM, Sulkin SE, Schulze ML. Continuing importance of laboratory-acquired infections. Am J Public Health 1965;55:0–9

    CAS  Google Scholar 

  10. Pike RM. Laboratory associated infections: incidence, fatalities, causes and prevention. Annu Rev Microbiol 1979;33:41–66

    Article  PubMed  CAS  Google Scholar 

  11. Centers for Disease Control. Classification of Etiologic Agents on the Basis of Hazard (4th ed). Atlanta: US Department of Health, Education and Welfare, Public Health Service, 1974

    Google Scholar 

  12. Recombinant DNA guidelines. Fed Register 1976;41:27902–27943

    Google Scholar 

  13. Guidelines for research involving recombinant DNA molecules. Fed Register 1986;51:16958–16968

    Google Scholar 

  14. Office of Research Safety, National Cancer Institute and the Special Committee of Safety and Health Experts. Laboratory Safety Monograph: A Supplement to the NIH Guidelines for Recombinant DNA Research. Bethesda: National Institutes of Health, 1978

    Google Scholar 

  15. Centers for Disease Control and Prevention and the National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (3rd ed). HHS Publ. No. (CDC) 93–8395. Atlanta: US Department of Health and Human Services, Public Health Service, 1993

    Google Scholar 

  16. Marcus R, Kay K, Mann JM. Transmission of human immunodeficiency virus (HIV) in healthcare settings worldwide. Bull WHO 89;67:577–582

    Google Scholar 

  17. Centers for Disease Control. Recommendations for prevention of HIV transmission in health-care settings. MMWR 1987;36(suppl 2):3S–18S

    Google Scholar 

  18. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in healthcare settings. MMWR 1988;37:377–382, 387, 388

    Google Scholar 

  19. Centers for Disease Control. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989;38:5–6

    Google Scholar 

  20. Centers for Disease Control and Prevention. Recommended infection control practices for dentistry. MMWR 1993;42:RR-8

    Google Scholar 

  21. US Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens, final rule. Fed Register 91;56:64175–64182

    Google Scholar 

  22. Metier R, Ciesielski C, Ward J, Marcus R. HIV seroconversions in clinical laboratory workers following occupational exposure, United States [abstract PoC 4147]. In: Poster Abstracts, VIII International Conference on AIDS, Amsterdam, 1992:C269

    Google Scholar 

  23. Kennedy ME. Biosafety: principles and practices in the human immunodeficiency laboratory. In Schochetman G, George JR (eds): AIDS Testing: Methodology and Management Issues. New York: Springer-Verlag, 1992: 181–186

    Google Scholar 

  24. National Committee for Clinical Laboratory Standards. Protection of Laboratory Workers from Infections Transmitted by Blood, Body Fluids and Tissues. NCCLS Document M29–T2. 1992:11(14)

    Google Scholar 

  25. Schochetman G, George JR. AIDS Testing: Methodology and Management Issues. New York: Springer-Verlag, 1991

    Google Scholar 

  26. Interstate shipment of etiologic agents. Fed Register 1942;CFR part 72

    Google Scholar 

  27. Richmond JY. Developing a response to medical waste issues. ASM News 1990;56:420–423

    Google Scholar 

  28. Castro KG, Polder JA. Management of occupational exposure to the human immunodeficiency virus. In Schochetman G, George JR (eds): AIDS Testing: Methodology and Management Issues. New York: Springer-Verlag, 1992: 204–207

    Google Scholar 

  29. Richmond JY. Safe practices and procedures for working with human specimens in biomedical research laboratories. J Clin Immunoassay 88;11(3): 115–121

    Google Scholar 

  30. Centers for Disease Control. Public health statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(No. RR-17)

    Google Scholar 

Download references

Authors
  1. Jonathan Y. Richmond
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory Investigations Branch Division of HIV/AIDS, National Center for Infectious Diseases Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA

    Gerald Schochetman Ph.D. (Chief) (Chief)

  2. Developmental Technology Section Laboratory Investigations Branch Division of HIV/AIDS, National Center for Infectious Diseases Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA

    J. Richard George Ph.D. (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Richmond, J.Y. (1994). HIV Biosafety: Guidelines and Regulations. In: Schochetman, G., George, J.R. (eds) AIDS Testing. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-0867-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-0867-9_22

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-6927-4

  • Online ISBN: 978-1-4612-0867-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation